Verified source report
STAT+: FDA reverses course on Regenxbio’s childhood gene therapy after rejection
The FDA will reconsider approving Regenxbio's experimental gene therapy for a deadly and rare childhood brain disorder it rejected just four months ago.
coverage / Source report
What happened
According to STAT’s source item, STAT+: FDA reverses course on Regenxbio’s childhood gene therapy after rejection, The FDA will reconsider approving Regenxbio’s experimental gene therapy for a deadly and rare childhood brain disorder it rejected just four months ago.
Context
The development sits in VINI’s Science file for readers following research, health, climate, space, medicine, and scientific institutions. The original report is linked so readers can check the source account, follow later updates, and compare new coverage against the first published record. The source item is dated 2026-06-22T10:43:36+00:00.
What to watch
Open questions include whether primary sources issue follow-up statements, whether local or market impacts become clearer, and whether additional reporting changes the timeline or adds material context.
Source
Primary source: STAT+: FDA reverses course on Regenxbio’s childhood gene therapy after rejection via STAT. VINI cites and links the source; it does not reproduce the publisher’s full article text without rights clearance.
This source-cited VINI report links to the original publisher record. VINI does not republish third-party article bodies without rights clearance. 1 source listed.
Source links
- STAT+: FDA reverses course on Regenxbio’s childhood gene therapy after rejectionSTAT - 2026-06-22T10:43:36+00:00
Reader comments
Moderated discussion
Comments are open to authenticated approved accounts, screened for spam and abuse, and published only after newsroom moderation unless editors change the story control.